The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Glycemia reduction in type 2 diabetes–microvascular and cardiovascular outcomes
Open accessAbstract
BACKGROUND: Data are lacking on the comparative effectiveness of commonly used glucose-lowering medications, when added to metformin, with respect to microvascular and cardiovascular disease outcomes in persons with type 2 diabetes. METHODS: of body-surface area, diabetic peripheral neuropathy assessed with the Michigan Neuropathy Screening Instrument, cardiovascular events (major adverse cardiovascular events [MACE], hospitalization for heart failure, or an aggregate outcome of any cardiovascular event), and death. Hazard ratios are presented with 95% confidence limits that are not adjusted for multiple comparisons. RESULTS: During a mean 5.0 years of follow-up in 5047 participants, there were no material differences among the interventions with respect to the development of hypertension or dyslipidemia or with respect to microvascular outcomes; the mean overall rate (i.e., events per 100 participant-years) of moderately increased albuminuria levels was 2.6, of severely increased albuminuria levels 1.1, of renal impairment 2.9, and of diabetic peripheral neuropathy 16.7. The treatment groups did not differ with respect to MACE (overall rate, 1.0), hospitalization for heart failure (0.4), death from cardiovascular causes (0.3), or all deaths (0.6). There were small differences with respect to rates of any cardiovascular disease, with 1.9, 1.9, 1.4, and 2.0 in the glargine, glimepiride, liraglutide, and sitagliptin groups, respectively. When one treatment was compared with the combined results of the other three treatments, the hazard ratios for any cardiovascular disease were 1.1 (95% confidence interval [CI], 0.9 to 1.3) in the glargine group, 1.1 (95% CI, 0.9 to 1.4) in the glimepiride group, 0.7 (95% CI, 0.6 to 0.9) in the liraglutide group, and 1.2 (95% CI, 1.0 to 1.5) in the sitagliptin group. CONCLUSIONS: In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups. The findings indicated possible differences among the groups in the incidence of any cardiovascular disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; GRADE ClinicalTrials.gov number, NCT01794143.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although no significant differences were found for major adverse cardiovascular events, hospitalization for HF, or cardiovascular death (133).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 287
RetractedHemmingsen, B., Lund, S. S., Gluud, C. N., Vaag, A. A., Almdal, T., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 210
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–159 of 159
Gonzalez, J. S., Wen, H., BUTERA, N. M., Uschner, D., Krause-Steinrauf, H. J., Gramzinski, M. R., Wexler, D. J., Petrovitch, H., Hoogendoorn, C. J., Crespo-Ramos, G., et al. (2026) · Diabetes Care · doi:10.2337/dc25-2008 · Cited by 1
Lin, Y., Du, K., & Tian, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1711633 · Cited by 1
Zhou, J., Yu, Y., Song, L., Qian, P., Zhao, M., Ding, F. W. X., Lian, X., & Yu, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1854350 · Cited by 1
Zhang, F., Wang, S., Zhao, C., Jiang, D., Wang, Y., Qi, J., & Li, Y. (2023) · Tissue and Cell · doi:10.1016/j.tice.2023.102031 · Cited by 1
Yu, S., Wei, D., & Shi, N. (2023) · PubMed Central · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Mačáková, D., Krystyník, O., Cibičková, Ľ., & Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.009 · Cited by 1
Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE
Riddle, M. C. (2024) · Diabetes Care · doi:10.2337/dci24-0008 · Cited by 1
Vildagliptin: Benchmarks of Rational Prescribing for a Busy General Practitioner
Голубев, С. А. (2024) · Рецепт · doi:10.34883/pi.2024.27.2.007 · Cited by 1
Confederat, L. G., Stefan, R., Condurache, I., & Dragostin, O.-M. (2024) · Clinics and Practice · doi:10.3390/clinpract15010007 · Cited by 1
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Thomas, T. S., & Srinivasa, S. (2024) · PubMed Central · Cited by 1
Liu, Z., Hu, H., Zeng, J., & Jiang, M. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01627-6 · Cited by 1
Wei, L. (2025) · American Journal of Translational Research · doi:10.62347/dyym9265 · Cited by 1
Ghotbi, E., Bluemke, D. A., Hathaway, Q. A., Klein, J. G., Shabani, M., Akhtarkhavari, S., Barr, R. G., Bancks, M. P., Post, W. S., Budoff, M. J., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11778-9 · Cited by 3
Lu, M., Zhou, H., Liu, Y., Song, J., Lü, X., & Liu, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s535766 · Cited by 1
Brave New World: Improving Obesity and Preventing Cardiovascular Disease
O’Keefe, J. H., O’Keefe, E. L., Nassif, M. E., & Lavie, C. J. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.11.012 · Cited by 1
Lanthier, L., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2022) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2022.11.005
Morales-Villegas, E. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3207
Krome, S. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-1988-4641
Commentary on glucose reduction in type 2 diabetes ( GRADE )
Lee, Y.-T., Gu, Y., & Jiang, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13994
Krome, S. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1953-8113
Wie es nach Metformin weiter geht
Sonnet, M. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4491-8
Les meilleures études en 2022 adéquates pour les soins de première ligne
Perry, D., Moe, S. S., Thomas, B., Lindblad, A. J., Kirkwood, J. E. M., Falk, J., Potter, J., Paige, A., & Allan, G. M. (2023) · Canadian Family Physician · doi:10.46747/cfp.6905e103
Lehrke, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01034-3
Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht
Schirmer, S. H. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4512-7
Xue, Y., Tian, M., Li, M., Jiang, X., Cao, J., Zhou, Y., Liu, Y., & Ma, H. (2023) · Research Square · doi:10.21203/rs.3.rs-3242707/v1
Profil Neuropati Perifer dan Korelasinya dengan Kadar Gula Darah Sewaktu di Panti Lansia Santa Anna
Sim, A. S., Wijaya, D. A., Nathaniel, F., Yogie, G. S., Firmansyah, Y., Sugiarto, H., Amadea, S., & Santoso, A. H. (2023) · Malahayati Nursing Journal · doi:10.33024/mnj.v5i9.11121
Stehouwer, C. D. A., Serné, E. H., de Jong, H. J. I., Overbeek, J. A., & Palmen, J. (2023) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-023-1227-2
David M. Nathan: An Epic Investigator, An Epoch in Diabetes Care
Wexler, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0095
Physician, U. T. D. M., Molina, J. E. A., Valdez, N. A. M., Physician, U. L. E. A. D. M., Corredor, D. A. V., Medicine, U. E. D. G., Cruzatty, J. M. V., Physician, U. L. E. A. D. M., Alfonso, A. F., Physician, S. I. I. C. A. E., et al. (2024) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v4-i03-29
Livia, W., Murti, B., Tamtomo, D. G., & Prasetya, H. (2024) · Journal of Epidemiology and Public Health · doi:10.26911/jepublichealth.2024.09.01.10
Ultrasound Features of the Peroneal Nerve in Type 2 Diabetes Mellitus
Stefanenko, A. V., Bagriy, A. E., Олеговна, О. А., Михайличенко, Е. С., Вадимовна, П. А., & Stefanenko, E. R. (2024) · Актуальные проблемы медицины · doi:10.52575/2687-0940-2024-47-2-143-157
Clinical Perspectives for Diagnosis and Treatment of Diabetic CardiomyopathyPreprint
Chen, D., Sindone, A. P., Huang, M. L. H., Peter, K., & Jenkins, A. J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5072684
Huang, A., Roberts, A. J. C., Mohsenian, Y., & Kim, G. E. (2025) · Clinical Diabetes · doi:10.2337/cd24-0070
4. Blood glucose-lowering therapies – Insulin options for type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112148
Albasheer, O. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072353980250418211500 · Cited by 1
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE
Hsia, D. S., Younes, N., Ghosh, A., Kazemi, E. J., Buse, J. B., Buse, J. B., Baker, C., Brown-Friday, J., Diaz, E., Diner, J., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2839
Zheng, Z.-C., Wang, X., & Fu, L. (2025) · Cureus · doi:10.7759/cureus.88691
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Kroon, L. A., & Zhou, C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch08
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., Strippoli, G. F., & Transplant, S. B. C. K. A. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015906.pub2 · Cited by 1
Wretlind, A., Curovic, V. R., de Zawadzki, A., Suvitaival, T., Xu, J., Zobel, E. H., von Scholten, B. J., Ripa, R. S., Kjaer, A., Hansen, T. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26619862
Zhang, L., Liu, H.-H., Yang, F., Zhang, Z.-Y., Wu, Y., Li, F., Dang, S., Zhang, Z.-Y., Qian, L.-L., & Wang, R.-X. (2023) · Figshare · doi:10.6084/m9.figshare.24180843
The Risk of Hypothyroidism With the Use of GLP ‐1 Receptor Agonists in Saudi Arabia
Alfakhri, A., Almadani, O. A., Alroba, R., Alrwisan, A. A., Alshaya, O. A., & Albogami, Y. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70315
Li, Z., Guan, X.-C., Li, X., Chen, Y.-Y., Ruan, F., & Long, L. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05518-0
Thirumalai, A., & Hirsch, I. B. (2026) · Diabetes Care · doi:10.2337/dci26-0040
Cardiovascular Implications of Diabetes Mellitus: A Systematic Literature Review
Gupta, P. K., Anand Sekar, G., Diwakar, R., Panchal, N. A., Kumar, A., & Bhaumik, A. (2026) · Cureus · doi:10.7759/cureus.109607
Martens, T. W., Asche, S. E., JaKa, M. M., Johnson, M. L., DUNNIGAN, S. M., Haven, A. L., Morris, C., Barnaby, D., Maciosek, M. V., Dinh, J. M., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108357
Liao, J., Huang, Y., & Yue, R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70876
Lugo-Palacios, D. G., Bidulka, P., Charlton, P., Huston, B., Carnegie, A. C., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., et al. (2025) · Health Technology Assessment · doi:10.3310/asdb8011
Chaulagain, S., pandey, M., Saurav, S., Malla, D., Agrawal, K., Khatiwada, S., Koirala, T. N., & Aushili, M. (2026) · Cureus · doi:10.7759/cureus.110712
Lansang, M. C., Petito, L. C., Hegermiller, E., Chelliah, I., Carnahan, R. M., McDonnell, M. E., DEVRIES, A. R., Priest, E., Willey, V., Nair, V. P., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0027
Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone
Bea, S., Lee, H., Cho, Y. M., Choi, Y., Shin, J., & Bykov, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71082
Lu, G., Wang, X., Zhuang, H., Wang, X., Zhou, X., & Zhao, G. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179387
Antidiabetic drugs and its pharmacological profile target in human for type 2 diabetes mellitus
Guzmán, D. C., Brizuela, N. O., Peraza, A. V., Olguı́n, H. J., Herrera, M. O., Jiménez, F. T., del Angel, D. S., & García, E. H. (2026) · Discover Medicine · doi:10.1007/s44337-026-00659-9
Tang, M., Nathan, D. M., Wexler, D. J., Putman, M. S., Higgins, J. M., Zheng, H., Rhee, E. P., de Boer, I. H., & Kalim, S. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109439
Metadata
- Authors
- The GRADE Study Research Group
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- The GRADE Study Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1075-1088
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9832916
- OpenAlex
- W4296702407
- Cited by
- 159
- References
- 25
- Citations by year
- 2026: 22 · 2025: 39 · 2024: 42 · 2023: 51 · 2022: 5
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- Centers for Disease Control and Prevention
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK098246, U34DK088043)
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, glycemic control, glucose-lowering medications, metformin, glargine, glimepiride, liraglutide, sitagliptin, microvascular complications, diabetic peripheral neuropathy, albuminuria, renal dysfunction, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, comparative effectiveness
- MeSH terms
- Sitagliptin Phosphate, Insulin Glargine, Liraglutide, Albuminuria, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Drug Therapy, Combination, Glomerular Filtration Rate, Heart Failure, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Metformin, Sulfonylurea Compounds, Diabetes Complications, Dyslipidemias, Microvessels, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
